Skip to main content

Glucotrol Side Effects

Generic name: glipizide

Medically reviewed by Last updated on Jun 12, 2023.

Note: This document contains side effect information about glipizide. Some dosage forms listed on this page may not apply to the brand name Glucotrol.

Applies to glipizide: oral tablet, oral tablet extended release.

Serious side effects of Glucotrol

Along with its needed effects, glipizide (the active ingredient contained in Glucotrol) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking glipizide:

Less common


Incidence not known

Other side effects of Glucotrol

Some side effects of glipizide may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

Less common


Incidence not known

For Healthcare Professionals

Applies to glipizide: compounding powder, oral tablet, oral tablet extended release.


The more commonly reported side effects have included dizziness, diarrhea, nervousness, tremor, hypoglycemia, and flatulence.[Ref]


Common (1% to 10%): Hypoglycemia

Uncommon (less than 1%): Thirst

Frequency not reported: Disulfiram like reactions, hepatic porphyria, hyponatremia, syndrome of inappropriate antidiuretic hormone (SIADH), elevation of LDH[Ref]

Disulfiram-like reactions have been reported with sulfonylureas. Clinical experience has shown this drug to have a low incidence of disulfiram-like alcohol reactions.[Ref]


Frequency not reported: Leucopenia, agranulocytosis, thrombocytopenia, aplastic anemia, hemolytic anemia, pancytopenia[Ref]


Common (1% to 10%): Syncope

Uncommon (less than 1%): Arrhythmia, flushing, hypertension[Ref]


Frequency not reported: Impaired hepatic function, hepatitis, jaundice, mild to moderate ALT, LDH, alkaline phosphatase elevations

Postmarketing reports: Cholestatic and hepatocellular forms of liver injury accompanied by jaundice[Ref]


Dermatologic side effects frequently disappear with continued therapy. Photosensitivity has been reported with other sulfonylureas.[Ref]

Common (1% to 10%): Sweating, pruritus

Uncommon (less than 1%): Rash, urticaria

Frequency not reported: Rash, erythema, morbilliform or maculopapular eruptions, urticaria, pruritus, eczema[Ref]


Common (1% to 10%): Nausea, diarrhea, constipation, gastralgia, vomiting, flatulence, dyspepsia

Uncommon (less than 1%): Anorexia, trace blood in stool

Frequency not reported: Gastrointestinal irritation, gastrointestinal bleeding

Postmarketing reports: Abdominal pain[Ref]

Gastrointestinal side effects appear to be dose-related and may disappear on division or reduction of dosage.[Ref]


Common (1% to 10%): Polyuria

Uncommon (less than 1%): Dysuria[Ref]


Common (1% to 10%): Arthralgia, leg cramps, myalgia[Ref]

Nervous system

Common (1% to 10%): Headache, dizziness, nervousness, tremors, paresthesia, hypesthesia

Uncommon (less than 1%): Migraine

Frequency not reported: Drowsiness[Ref]


Common (1% to 10%): Blurred vision

Uncommon (less than 1%): Pain in the eye, conjunctivitis, retinal hemorrhage

Frequency not reported: Diplopia, abnormal vision, visual impairment, decreased vision[Ref]


Common (1% to 10%): Asthenia, pain

Uncommon (less than 1%): Chills, edema

Frequency not reported: Vertigo, malaise[Ref]


Common (1% to 10%): Insomnia, anxiety, depression

Frequency not reported: Confusion[Ref]


Common (1% to 10%): Rhinitis

Uncommon (less than 1%): Pharyngitis, dyspnea[Ref]


Frequency not reported: Mild to moderate BUN and creatinine elevations


1. (2002) "Product Information. Glucotrol (glipizide)." Pfizer U.S. Pharmaceuticals

2. Cerner Multum, Inc. "UK Summary of Product Characteristics."

3. Cerner Multum, Inc. "Australian Product Information."

4. Feinglos MN, Lebovitz HE (1983) "Long-term safety and efficacy of glipizide." Am J Med, 75, p. 60-6

5. Moder KG, Schwenk NM (1991) "A coproporphyria-like syndrome induced by glipizide." Mayo Clin Proc, 66, p. 312-6

6. Asplund K, Wiholm BE, Lundman B (1991) "Severe hypoglycaemia during treatment with glipizide." Diabet Med, 8, p. 726-31

7. Brogden RN, Heel RC, Pakes GE, Speight TM, Avery GS (1979) "Glipizide: a review of its pharmacological properties and therapeutic use." Drugs, 18, p. 329-53

8. Lebovitz HE (1985) "Glipizide: a second-generation sulfonylurea hypoglycemic agent. Pharmacology, pharmacokinetics and clinical use." Pharmacotherapy, 5, p. 63-77

9. Prendergast BD (1984) "Glyburide and glipizide, second-generation oral sulfonylurea hypoglycemic agents." Clin Pharm, 3, p. 473-85

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.